Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis

IF 10.3 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Heart failure Pub Date : 2025-07-03 DOI:10.1016/j.jchf.2025.102549

Giulio Sinigiani MD , Giuseppe Damiano Sanna MD, PhD , Alberto Aimo MD, PhD , Aldostefano Porcari MD , Giacomo Bonacchi MD , Laura De Michieli MD, PhD , Paolo Milani MD, PhD , Giuseppe Vergaro MD, PhD , Giacomo Tini MD, PhD , Marco Baldan MD , Paola Martire MD , Alberto Beghini MD , Daniela Tomasoni MD , Giuseppe Palmiero MD , Paolo Ossola MD , Francesco Musca MD , Mattia Zampieri MD, PhD , Gabriele Guidi Colombi MD , Matteo Serenelli MD, PhD , Roberto Cemin MD , Alberto Cipriani MD

引用次数: 0

查看原文本刊更多论文

NYHA功能级I和II型野生型转甲状腺素型心肌病患者接受他法非地治疗的结局和疾病进展

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC. Heart failure CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

21.20

自引率

2.30%

发文量

164

期刊介绍： JACC: Heart Failure publishes crucial findings on the pathophysiology, diagnosis, treatment, and care of heart failure patients. The goal is to enhance understanding through timely scientific communication on disease, clinical trials, outcomes, and therapeutic advances. The Journal fosters interdisciplinary connections with neuroscience, pulmonary medicine, nephrology, electrophysiology, and surgery related to heart failure. It also covers articles on pharmacogenetics, biomarkers, and metabolomics.